Advanced Therapy Based on Gene - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512245803

Publication Date:

December 6, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Advanced Therapy Based on Gene is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
The global market for Advanced Therapy Based on Gene was estimated to be worth US$ 9063 million in 2023 and is forecast to a readjusted size of US$ 34850 million by 2030 with a CAGR of 20.2% during the forecast period 2024-2030
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Advanced Therapy Based on Gene, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Advanced Therapy Based on Gene by region & country, by Type, and by Application.
The Advanced Therapy Based on Gene market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Advanced Therapy Based on Gene.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type:
Viral
Non-viral
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Advanced Therapy Based on Gene manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Advanced Therapy Based on Gene in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Advanced Therapy Based on Gene in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Advanced Therapy Based on Gene Product Introduction
1.2 Global Advanced Therapy Based on Gene Market Size Forecast
1.3 Advanced Therapy Based on Gene Market Trends & Drivers
1.3.1 Advanced Therapy Based on Gene Industry Trends
1.3.2 Advanced Therapy Based on Gene Market Drivers & Opportunity
1.3.3 Advanced Therapy Based on Gene Market Challenges
1.3.4 Advanced Therapy Based on Gene Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Advanced Therapy Based on Gene Players Revenue Ranking (2023)
2.2 Global Advanced Therapy Based on Gene Revenue by Company (2019-2024)
2.3 Key Companies Advanced Therapy Based on Gene Manufacturing Base Distribution and Headquarters
2.4 Key Companies Advanced Therapy Based on Gene Product Offered
2.5 Key Companies Time to Begin Mass Production of Advanced Therapy Based on Gene
2.6 Advanced Therapy Based on Gene Market Competitive Analysis
2.6.1 Advanced Therapy Based on Gene Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Advanced Therapy Based on Gene Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Advanced Therapy Based on Gene as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Viral
3.1.2 Non-viral
3.2 Global Advanced Therapy Based on Gene Sales Value by Type
3.2.1 Global Advanced Therapy Based on Gene Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Advanced Therapy Based on Gene Sales Value, by Type (2019-2030)
3.2.3 Global Advanced Therapy Based on Gene Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Neurological Diseases
4.1.2 Cancer
4.1.3 Other
4.2 Global Advanced Therapy Based on Gene Sales Value by Application
4.2.1 Global Advanced Therapy Based on Gene Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Advanced Therapy Based on Gene Sales Value, by Application (2019-2030)
4.2.3 Global Advanced Therapy Based on Gene Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Advanced Therapy Based on Gene Sales Value by Region
5.1.1 Global Advanced Therapy Based on Gene Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Advanced Therapy Based on Gene Sales Value by Region (2019-2024)
5.1.3 Global Advanced Therapy Based on Gene Sales Value by Region (2025-2030)
5.1.4 Global Advanced Therapy Based on Gene Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Advanced Therapy Based on Gene Sales Value, 2019-2030
5.2.2 North America Advanced Therapy Based on Gene Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Advanced Therapy Based on Gene Sales Value, 2019-2030
5.3.2 Europe Advanced Therapy Based on Gene Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Advanced Therapy Based on Gene Sales Value, 2019-2030
5.4.2 Asia Pacific Advanced Therapy Based on Gene Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Advanced Therapy Based on Gene Sales Value, 2019-2030
5.5.2 South America Advanced Therapy Based on Gene Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Advanced Therapy Based on Gene Sales Value, 2019-2030
5.6.2 Middle East & Africa Advanced Therapy Based on Gene Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Advanced Therapy Based on Gene Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Advanced Therapy Based on Gene Sales Value
6.3 United States
6.3.1 United States Advanced Therapy Based on Gene Sales Value, 2019-2030
6.3.2 United States Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Advanced Therapy Based on Gene Sales Value, 2019-2030
6.4.2 Europe Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Advanced Therapy Based on Gene Sales Value, 2019-2030
6.5.2 China Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.5.3 China Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Advanced Therapy Based on Gene Sales Value, 2019-2030
6.6.2 Japan Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Advanced Therapy Based on Gene Sales Value, 2019-2030
6.7.2 South Korea Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Advanced Therapy Based on Gene Sales Value, 2019-2030
6.8.2 Southeast Asia Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Advanced Therapy Based on Gene Sales Value, 2019-2030
6.9.2 India Advanced Therapy Based on Gene Sales Value by Type (%), 2023 VS 2030
6.9.3 India Advanced Therapy Based on Gene Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Profile
7.1.2 Biogen Main Business
7.1.3 Biogen Advanced Therapy Based on Gene Products, Services and Solutions
7.1.4 Biogen Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.1.5 Biogen Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis Advanced Therapy Based on Gene Products, Services and Solutions
7.2.4 Novartis Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.2.5 Novartis Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Profile
7.3.2 Gilead Sciences Main Business
7.3.3 Gilead Sciences Advanced Therapy Based on Gene Products, Services and Solutions
7.3.4 Gilead Sciences Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.3.5 Sarepta Therapeutics Recent Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Profile
7.4.2 Sarepta Therapeutics Main Business
7.4.3 Sarepta Therapeutics Advanced Therapy Based on Gene Products, Services and Solutions
7.4.4 Sarepta Therapeutics Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.4.5 Sarepta Therapeutics Recent Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Profile
7.5.2 Alnylam Pharmaceuticals Main Business
7.5.3 Alnylam Pharmaceuticals Advanced Therapy Based on Gene Products, Services and Solutions
7.5.4 Alnylam Pharmaceuticals Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.5.5 Alnylam Pharmaceuticals Recent Developments
7.6 Amgen
7.6.1 Amgen Profile
7.6.2 Amgen Main Business
7.6.3 Amgen Advanced Therapy Based on Gene Products, Services and Solutions
7.6.4 Amgen Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.6.5 Amgen Recent Developments
7.7 Spark Therapeutics
7.7.1 Spark Therapeutics Profile
7.7.2 Spark Therapeutics Main Business
7.7.3 Spark Therapeutics Advanced Therapy Based on Gene Products, Services and Solutions
7.7.4 Spark Therapeutics Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.7.5 Spark Therapeutics Recent Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Profile
7.8.2 Akcea Therapeutics Main Business
7.8.3 Akcea Therapeutics Advanced Therapy Based on Gene Products, Services and Solutions
7.8.4 Akcea Therapeutics Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.8.5 Akcea Therapeutics Recent Developments
7.9 Sunway Biotech
7.9.1 Sunway Biotech Profile
7.9.2 Sunway Biotech Main Business
7.9.3 Sunway Biotech Advanced Therapy Based on Gene Products, Services and Solutions
7.9.4 Sunway Biotech Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.9.5 Sunway Biotech Recent Developments
7.10 SIBIONO
7.10.1 SIBIONO Profile
7.10.2 SIBIONO Main Business
7.10.3 SIBIONO Advanced Therapy Based on Gene Products, Services and Solutions
7.10.4 SIBIONO Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.10.5 SIBIONO Recent Developments
7.11 AnGes
7.11.1 AnGes Profile
7.11.2 AnGes Main Business
7.11.3 AnGes Advanced Therapy Based on Gene Products, Services and Solutions
7.11.4 AnGes Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.11.5 AnGes Recent Developments
7.12 Orchard Therapeutics
7.12.1 Orchard Therapeutics Profile
7.12.2 Orchard Therapeutics Main Business
7.12.3 Orchard Therapeutics Advanced Therapy Based on Gene Products, Services and Solutions
7.12.4 Orchard Therapeutics Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.12.5 Orchard Therapeutics Recent Developments
7.13 Human Stem Cells Institute
7.13.1 Human Stem Cells Institute Profile
7.13.2 Human Stem Cells Institute Main Business
7.13.3 Human Stem Cells Institute Advanced Therapy Based on Gene Products, Services and Solutions
7.13.4 Human Stem Cells Institute Advanced Therapy Based on Gene Revenue (US$ Million) & (2019-2024)
7.13.5 Human Stem Cells Institute Recent Developments
8 Industry Chain Analysis
8.1 Advanced Therapy Based on Gene Industrial Chain
8.2 Advanced Therapy Based on Gene Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Advanced Therapy Based on Gene Sales Model
8.5.2 Sales Channel
8.5.3 Advanced Therapy Based on Gene Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂